Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Roche has ended development of olesoxime, a small molecule designed to protect nerve cells in spinal muscular atrophy. In 2015, the big pharma firm paid roughly $140 million to acquire olesoxime from Trophos, and it had hoped to begin a Phase III study of the compound later this year. But in a letter to SMA patient advocacy groups, Roche said it had struggled with the formulation of the drug. And because of newly available treatments for SMA, the company chose to end its efforts in the area.
This article has been sent to the following recipient: